C-MER Medical Holdings (SZSC:3309) - Stock Price, News & Analysis

3309 Stock Overview

An investment holding company, provides ophthalmic services under the C-MER Dennis Lam brand name in Hong Kong and Mainland China.

About the company

3309 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 73.3% below our estimate of its fair value

Became profitable this year

Risk Analysis

3309 passed our risk checks.

C-MER Medical Holdings Limited Competitors

Chaoju Eye Care Holdings

SEHK:2219

HK$2.4b

Rici Healthcare Holdings

SEHK:1526

HK$1.9b

China Resources Medical Holdings

SEHK:1515

HK$5.6b

Honliv Healthcare Management Group

SEHK:9906

HK$1.4b

Price History & Performance

Summary of all time highs, changes and price drops for C-MER Medical Holdings
Historical stock prices
Current Share Price	HK$2.81
52 Week High	HK$3.98
52 Week Low	HK$1.81
Beta	0.56
11 Month Change	26.58%
3 Month Change	3.69%
1 Year Change	-24.26%
33 Year Change	-65.31%
5 Year Change	-44.79%
Change since IPO	-36.85%

Recent updates

Shareholder Returns

	3309	HK Healthcare	HK Market
7D	31.9%	19.6%	13.0%
1Y	-24.3%	-24.9%	16.1%

Return vs Industry: 3309 matched the Hong Kong Healthcare industry which returned -24.9% over the past year.

Return vs Market: 3309 underperformed the Hong Kong Market which returned 16.1% over the past year.

Price Volatility

Is 3309's price volatile compared to industry and market?
3309 volatility
3309 Average Weekly Movement	8.0%
Healthcare Industry Average Movement	6.7%
Market Average Movement	7.1%
10% most volatile stocks in HK Market	14.7%
10% least volatile stocks in HK Market	3.6%

Stable Share Price: 3309's share price has been volatile over the past 3 months.

Volatility Over Time: 3309's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2012	2,192	Dennis Lam	www.cmermedical.com

C-MER Medical Holdings Limited, an investment holding company, provides ophthalmic services under the C-MER Dennis Lam brand name in Hong Kong and Mainland China. The company operates through four segments: HK Medical Business, Sales of Medical Consumables, Mainland China Ophthalmic Business, and Mainland China Dental Business. It provides dental, oncology, medical aesthetics, and laboratory services; and engages in the sale of vision aid products, such as glasses and lens, and medical consumables.

C-MER Medical Holdings Limited Fundamentals Summary

How do C-MER Medical Holdings's earnings and revenue compare to its market cap?
3309 fundamental statistics
Market cap	HK$3.45b
Earnings (TTM)	HK$63.00m
Revenue (TTM)	HK$1.90b

54.8x

P/E Ratio

1.8x

P/S Ratio

Is 3309 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3309 income statement (TTM)
Revenue	HK$1.90b
Cost of Revenue	HK$1.29b
Gross Profit	HK$607.94m
Other Expenses	HK$544.93m
Earnings	HK$63.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.051
Gross Margin	32.06%
Net Profit Margin	3.32%
Debt/Equity Ratio	1.0%

How did 3309 perform over the long term?

See historical performance and comparison

3309 Stock Overview

Rewards

Risk Analysis

C-MER Medical Holdings Limited Competitors

SEHK:2219

HK$2.4b

SEHK:1526

HK$1.9b

SEHK:1515

HK$5.6b

SEHK:9906

HK$1.4b

Price History & Performance

Recent News & Updates

Investor sentiment improves as stock rises 32%

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 21%

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

Recent updates

Investor sentiment improves as stock rises 32%

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 21%

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 22% undervalued after recent price drop

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86

First half earnings released

Independent Non-Executive Director recently bought HK$138k worth of stock

Independent Non-Executive Director recently bought HK$130k worth of stock

First half earnings released

C-MER Eye Care Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

Shareholder Returns

Price Volatility

About the Company

C-MER Medical Holdings Limited Fundamentals Summary

54.8x

1.8x

Earnings & Revenue